{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-024973","form_type":"8-K","ticker":"NNVC","cik":"0001379006","company_name":"NANOVIRICIDES, INC.","filed_at":"2024-02-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.003237+00:00","generated_at":"2026-06-06T00:09:46.499529+00:00","sec_items":["1.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"NanoViricides defers TheraCour milestone payments until revenue; CEO extends Line of Credit","bullets":["Amendment to TheraCour license defers future cash milestone payments (Milestones 4-7) until company achieves a Revenue Event; capped at 50% of Recognized Revenue.","Milestones 1,2,3 already paid: 100k Series A Preferred shares, 50k Series A Preferred shares, and $1.5M via 331,859 shares in lieu of cash.","CEO Dr. Anil Diwan extended $2M line of credit maturity from Dec 31, 2024 to Dec 31, 2025; no draws to date.","TheraCour agreed to suspend two-month advance payment requirement until company raises sufficient capital."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-024973","json":"https://secwatch.observer/filing/0001104659-24-024973.json","markdown":"https://secwatch.observer/filing/0001104659-24-024973.md","text":"https://secwatch.observer/filing/0001104659-24-024973.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1379006/000110465924024973/0001104659-24-024973-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1379006/000110465924024973/tm246547d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T00:09:46.499529+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2315ec42db7dff7904e8b46a59d7d17e14eef900","claim":"NANOVIRICIDES, INC. entered into Line of Credit Agreement with Dr. Anil R. Diwan valued at $2,000,000 (effective 2023-11-13).","evidence_excerpt":"on November 13, 2023, the Company and the Company’s President and CEO, Dr. Anil R. Diwan, entered into a Line of Credit Agreement whereby Dr. Diwan agreed to provide a standby Line of Credit to the Company in the maximum amount of $2,000,000.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1379006/000110465924024973/0001104659-24-024973-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"credit facility"},{"label":"Counterparty","value":"Dr. Anil R. Diwan"},{"label":"Value","value":"$2,000,000"},{"label":"Effective","value":"2023-11-13"}],"fact_type":"material_agreement"},{"claim_id":"39abbe2cd8623e146cdc99fb8d41e54caf1180f4","claim":"NANOVIRICIDES, INC. entered into License Agreement with TheraCour Pharma, Inc. (effective 2021-09-09).","evidence_excerpt":"NanoViricides, Inc. (the “Company”) entered into a License Agreement (the “License Agreement”) with TheraCour Pharma, Inc. (“TheraCour”) for an exclusive, worldwide license to the Company for further development with respect to TheraCour’s research and development of services with respect to treatments for coronavirus derived human infections.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1379006/000110465924024973/0001104659-24-024973-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"license"},{"label":"Counterparty","value":"TheraCour Pharma, Inc."},{"label":"Effective","value":"2021-09-09"}],"fact_type":"material_agreement"},{"claim_id":"6b10c31d7ca6879cb567306158a39ac76fdea322","claim":"NANOVIRICIDES, INC. amended Extension Agreement with Dr. Anil R. Diwan valued at $2,000,000 (effective 2024-02-12).","evidence_excerpt":"On February 12, 2024, the Company, pursuant to Article 2.5 of the Company’s Line of Credit Agreement with Dr. Anil R. Diwan, signed an Extension Agreement which extended the maturity date of the Company’s Line of Credit from December 31, 2024 to December 31, 2025.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1379006/000110465924024973/0001104659-24-024973-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Agreement","value":"credit facility"},{"label":"Counterparty","value":"Dr. Anil R. Diwan"},{"label":"Value","value":"$2,000,000"},{"label":"Effective","value":"2024-02-12"}],"fact_type":"material_agreement"},{"claim_id":"a6a8cf01002debd46dfe9909a756aee5ab79afa5","claim":"NANOVIRICIDES, INC. amended Amendment with TheraCour Pharma, Inc. (effective 2024-02-13).","evidence_excerpt":"Amendment to Coronavirus License Agreement As previously disclosed, on September 9, 2021, NanoViricides, Inc. (the “Company”) entered","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1379006/000110465924024973/0001104659-24-024973-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Agreement","value":"license"},{"label":"Counterparty","value":"TheraCour Pharma, Inc."},{"label":"Effective","value":"2024-02-13"}],"fact_type":"material_agreement"},{"claim_id":"d965effa1698bcd7b9bdc404af21cb3827da6c8e","claim":"NANOVIRICIDES, INC. amended a license with TheraCour Pharma, Inc. (effective 2024-02-12).","evidence_excerpt":"nto a License Agreement (the “License Agreement”) with TheraCour Pharma, Inc. (“TheraCour”) for an exclusive, worldwide license to the Company for further development with respect to TheraCour’s research and development of services with respect","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1379006/000110465924024973/0001104659-24-024973-index.htm","confidence":0.7,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Agreement","value":"license"},{"label":"Counterparty","value":"TheraCour Pharma, Inc."},{"label":"Effective","value":"2024-02-12"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}